Prostate cancer · 11 regimens
Cost vs Efficacy · 3 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Abiraterone and Olaparib Variant #01 | — | R 52 169 | 21d | — | ~42.1 mo | — | — | 1 |
Abiraterone and Apalutamide Variant #01 | — | R 44 103 | 28d | — | — | — | — | — |
Apalutamide monotherapy Variant #01 | — | R 33 772 | 28d | — | — | — | — | — |
Enzalutamide monotherapy Variant #01 | — | R 14 528 | 28d | ~4.2 mo | ~17.5 mo | ~5 | ~R 72 642 PFS proxy · indirect | 13 |
Abiraterone monotherapy Variant #01 | — | R 10 334 | 28d | ~4.9 mo | ~15.4 mo | ~6 | ~R 62 006 PFS proxy · indirect | 9 |
Ketoconazole, Hydrocortisone, Dutasteride Variant #01 | — | R 3 910 | 28d | — | — | — | — | — |
Ketoconazole and Hydrocortisone Variant #01 | — | R 3 620 | 28d | — | — | — | — | — |
Hydrocortisone monotherapy Variant #01 | — | R 254 | 28d | — | ~12.6 mo | — | — | — |
Prednisone monotherapy Variant #11 | — | R 22 | 7d | ~2.2 mo | ~14.1 mo | ~10 | ~R 215 PFS proxy · indirect | 8 |
Antiandrogen withdrawal Partial | — | — | — | — | — | — | — | — |
BAT Variant #01 Partial | — | — | 28d | ~5.7 mo | — | ~7 | — | — |
11 of 11 regimens shown